Table 4 Summary of efficacy data for RP2D and all treated patients (ORR, PFS, OS)

From: Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial

Efficacy outcomes

Part 1

RP2D

All

 

n = 61

n = 38

N = 87

ORR, n/N (%)

53/59 (89.8)

29/34 (85.3)

71/81 (87.7)

CR/sCR, n/N (%)

20/59 (33.9)

11/34 (33.3)

27/81 (33.3)

VGPR, n/N (%)

24/59 (40.7)

14/34 (42.4)

32/81 (39.5)

PR, n/N (%)

9/59 (15.3)

4/34 (11.8)

12/81 (14.8)

mPFS, months (95% CI)

20.0 (15.7–30.0)

NYR (13.7 to NYR)

21.8 (17.8- 32.5)

mOS, months (95% CI)

34.0 (24.0 to NYR)

NYR (NYR to NYR)

34.0 (24.4 to NYR)

Median follow-up, months (range)

17.1 (0.9–42.5)

13.9 (1.1–28.2)

14.5 (0.9–42.5)

  1. sCR, stringent complete response; PR, partial response.
  2. ORR, CR/sCR, VGPR, PR and disease progression were based on two consecutive response assessments. mPFS and mOS were based on intent to treat. Data on individual cohorts from Part 1 are in Extended Data Table 4.
Back to article page